Company News
Plus Therapeutics Up 6.7% FDA Orphan Nod
Plus Therapeutics shares jumped 6.7% after FDA granted Orphan Drug Designation to REYOBIQ for pediatric malignant gliomas and ependymoma.
Orphan designation provides seven-year market exclusivity, tax
